/GKOS
GKOS Stock - Glaukos Corporation
Healthcare|Medical - DevicesNYSE
$116.22+2.66%
+$3.01 (+2.66%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.90
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).56
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.92
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+2.8%upside
Target: $119.47
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GKOS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$115.06 – $117.38
TARGET (TP)$119.42
STOP LOSS$106.92
RISK/REWARD1:0.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.69
52W High$163.71
52W Low$73.16
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $383.48M | $314.71M | $282.86M | $294.01M | $224.96M |
| Gross Profit | $289.45M | $239.14M | $213.88M | $227.38M | $133.24M |
| Gross Margin | 75.5% | 76.0% | 75.6% | 77.3% | 59.2% |
| Operating Income | $-122,366,000 | $-128,700,000 | $-82,313,000 | $-32,872,000 | $-123,553,000 |
| Net Income | $-146,372,000 | $-134,661,000 | $-99,195,000 | $-49,593,000 | $-120,348,000 |
| Net Margin | -38.2% | -42.8% | -35.1% | -16.9% | -53.5% |
| EPS | $-2.77 | $-2.78 | $-2.09 | $-1.07 | $-2.70 |
Company Overview
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
9
64%
Hold / Neutral
5
36%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
9 Bullish5 Neutral/Bearish
Price Targets
$99
Average Target
↓ 14.9% Downside
Now
$42
Low
$99
Average
$200
High
Based on 20 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 27th 2025 | Wells Fargo | Upgrade | Overweight | $120 |
| October 1st 2025 | Goldman | Initiation | Buy | $103 |
| May 1st 2025 | Wells Fargo | Downgrade | Equal Weight | $86 |
| February 19th 2025 | Mizuho | Upgrade | Outperform | $200← $140 |
| December 11th 2024 | Citigroup | Upgrade | Buy | $162← $132 |
| December 6th 2024 | UBS | Initiation | Buy | $182 |
| December 2nd 2024 | Morgan Stanley | Downgrade | Underweight | $120 |
| July 10th 2024 | Citigroup | Downgrade | Neutral | $132 |
| May 6th 2024 | Jefferies | Upgrade | Buy | $125← $84 |
| December 21st 2023 | JP Morgan | Upgrade | Overweight | $91← $66 |
| December 4th 2023 | Morgan Stanley | Initiation | Equal Weight | $65 |
| November 28th 2023 | Truist | Initiation | Buy | $88 |
| November 8th 2023 | Wells Fargo | Upgrade | Overweight | $83← $75 |
| June 7th 2023 | Piper Sandler | Upgrade | Overweight | $80← $55 |
| December 22nd 2022 | Mizuho | Initiation | Neutral | $48 |
Earnings History & Surprises
GKOSBeat Rate
72%
Last 18 quarters
Avg Surprise
+8.5%
EPS vs Estimate
Beats / Misses
13/4
1 met exactly
Latest EPS
$-0.16
Q4 2025
EPS Surprise History
Q1 24
-12.5%
$-0.63vs$-0.56
Q2 24
-20.7%
$-0.70vs$-0.58
Q3 24
0.0%
$-0.52vs$-0.52
Q4 24
+46.2%
$-0.28vs$-0.52
Q1 25
-5.3%
$-0.40vs$-0.38
Q2 25
+33.3%
$-0.22vs$-0.33
Q3 25
+7.7%
$-0.24vs$-0.26
Q4 25
+40.7%
$-0.16vs$-0.27
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q1 2026 | Feb 19, 2026 | $-0.22 | — | — | — |
Q4 2025 | Oct 29, 2025 | $-0.27 | $-0.16 | +40.7% | ✓ BEAT |
Q3 2025 | Jul 30, 2025 | $-0.26 | $-0.24 | +7.7% | ✓ BEAT |
Q2 2025 | Apr 30, 2025 | $-0.33 | $-0.22 | +33.3% | ✓ BEAT |
Q1 2025 | Feb 20, 2025 | $-0.38 | $-0.40 | -5.3% | ✗ MISS |
Q4 2024 | Nov 4, 2024 | $-0.52 | $-0.28 | +46.2% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $-0.52 | $-0.52 | 0.0% | = MET |
Q2 2024 | May 1, 2024 | $-0.58 | $-0.70 | -20.7% | ✗ MISS |
Q1 2024 | Feb 21, 2024 | $-0.56 | $-0.63 | -12.5% | ✗ MISS |
Q4 2023 | Nov 1, 2023 | $-0.56 | $-0.50 | +10.7% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $-0.57 | $-0.55 | +3.5% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $-0.61 | $-0.59 | +3.3% | ✓ BEAT |
Q1 2023 | Feb 22, 2023 | $-0.56 | $-0.53 | +5.4% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $-0.53 | $-0.45 | +15.1% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $-0.44 | $-0.83 | -88.6% | ✗ MISS |
Q2 2022 | May 4, 2022 | $-0.52 | $-0.38 | +26.9% | ✓ BEAT |
Q1 2022 | Feb 22, 2022 | $-0.37 | $-0.31 | +16.2% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-0.23 | $-0.19 | +17.4% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.24 | $-0.11 | +54.2% | ✓ BEAT |
Latest News
Truist Securities Maintains Buy on Glaukos, Raises Price Target to $145
📈 PositiveBenzinga•Dec 18, 2025, 02:26 PM
Citigroup Maintains Buy on Glaukos, Raises Price Target to $125
📈 PositiveBenzinga•Dec 11, 2025, 09:02 PM•Also:
Needham Maintains Buy on Glaukos, Raises Price Target to $125
📈 PositiveBenzinga•Dec 9, 2025, 06:57 PM
JP Morgan Maintains Overweight on Glaukos, Raises Price Target to $120
📈 PositiveBenzinga•Oct 30, 2025, 08:59 PM
Citigroup Maintains Buy on Glaukos, Raises Price Target to $113
📈 PositiveBenzinga•Oct 30, 2025, 06:39 PM•Also:
Wells Fargo Maintains Overweight on Glaukos, Raises Price Target to $122
📈 PositiveBenzinga•Oct 30, 2025, 02:39 PM
Needham Maintains Buy on Glaukos, Raises Price Target to $117
📈 PositiveBenzinga•Oct 30, 2025, 11:27 AM
Glaukos shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
📈 PositiveBenzinga•Oct 30, 2025, 10:37 AM
BTIG Maintains Buy on Glaukos, Raises Price Target to $116
📈 PositiveBenzinga•Oct 30, 2025, 10:26 AM
Glaukos shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
📈 PositiveBenzinga•Oct 29, 2025, 08:08 PM
Glaukos Raises FY2025 Sales Guidance from $480.000M-$486.000M to $490.000M-$495.000M vs $484.630M Est
📈 PositiveBenzinga•Oct 29, 2025, 08:07 PM
Glaukos Q3 Adj. EPS $(0.16) Beats $(0.26) Estimate, Sales $133.537M Beat $122.540M Estimate
📈 PositiveBenzinga•Oct 29, 2025, 08:06 PM
Wells Fargo Upgrades Glaukos to Overweight, Raises Price Target to $120
📈 PositiveBenzinga•Oct 27, 2025, 11:16 AM
Glaukos falls as Medicare administrator contractors meeting draws concern
📉 NegativeSeeking Alpha•Oct 20, 2025, 08:18 PM
Glaukos shares are trading lower. The company announced that the FDA approved its Epioxa New Drug Application.
➖ NeutralBenzinga•Oct 20, 2025, 03:55 PM
BTIG Reiterates Buy on Glaukos, Maintains $104 Price Target
📈 PositiveBenzinga•Oct 20, 2025, 12:27 PM
The FDA Approves Glaukos' Epioxa HD/Epioxa As First Incision-Free, Topical Drug Therapy For Keratoconus, Epioxa Is Expected To Be Commercially Available In Q1 2026
📈 PositiveBenzinga•Oct 20, 2025, 11:04 AM
BTIG Maintains Buy on Glaukos, Lowers Price Target to $104
📈 PositiveBenzinga•Oct 13, 2025, 12:07 PM
Citigroup Maintains Buy on Glaukos, Lowers Price Target to $110
➖ NeutralBenzinga•Oct 7, 2025, 05:04 PM•Also:
Goldman Sachs Initiates Coverage On Glaukos with Buy Rating, Announces Price Target of $103
📈 PositiveBenzinga•Oct 1, 2025, 05:49 PM
Frequently Asked Questions about GKOS
What is GKOS's current stock price?
Glaukos Corporation (GKOS) is currently trading at $116.22 per share. The stock has moved +2.66% today.
What is the analyst price target for GKOS?
The average analyst price target for GKOS is $119.42, based on 1 analyst.
What sector is Glaukos Corporation in?
Glaukos Corporation operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NYSE exchange.
What is GKOS's market cap?
Glaukos Corporation has a market capitalization of $6.67 billion, making it a mid-cap company.
Does GKOS pay dividends?
No, Glaukos Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACLX
Arcellx, Inc.
$63.96
Mkt Cap: $3.5B
ALKS
Alkermes plc
$28.45
Mkt Cap: $4.7B
ARWR
Arrowhead Pharmaceuticals, Inc.
$68.16
Mkt Cap: $9.4B
BLCO
Bausch + Lomb Corporation
$16.98
Mkt Cap: $6.0B
BRKR
Bruker Corporation
$46.48
Mkt Cap: $7.1B
IRTC
iRhythm Technologies, Inc.
$174.17
Mkt Cap: $5.6B
MMSI
Merit Medical Systems, Inc.
$87.70
Mkt Cap: $5.2B
OSCR
Oscar Health, Inc.
$14.90
Mkt Cap: $3.8B
TFX
Teleflex Incorporated
$121.89
Mkt Cap: $5.4B
TMDX
TransMedics Group, Inc.
$127.67
Mkt Cap: $4.4B
Explore stocks similar to GKOS for comparison